Skip to main content
Toggle navigation
Home
Tweets by ACG 2022 Annual Meeting
Home
Browse by Presenter
Browse by Presenter
Browse by Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
R
Ramireddy, Srinivas
University of Texas Health Science Center
Hands-on Workshop - EMR/Polypectomy - GI Fellows Only
Srinivas Ramireddy
Hands-on Workshop - EMR/Polypectomy - GI Fellows Only
Srinivas Ramireddy
Reau, Nancy
Rush University Medical Center
Liver Disease and Pregnancy
Nancy Reau
Meet the Experts Breakfast Session - Q&A with Faculty from Bonus Session E (Women's Health)
Nancy Reau
What's New and What's Best for the Medical Treatment of NAFLD
Nancy Reau
Reddy, K. Rajender
University of Pennsylvania
22 - Terlipressin Treatment of Patients With Hepatorenal Syndrome Type 1 Decreased the Need for Renal Replacement Therapy in Transplant Recipients: A 12-Month Follow-Up of the CONFIRM Study
K. Rajender Reddy
Reeves, Vonda
GI Alliance
Q&A
Vonda Reeves
Q&A
Vonda Reeves
Q&A
Vonda Reeves
The Great Recalibration of 2022: Is it Time for a Career Change and What Does That Mean?
Vonda Reeves
Welcome and Introductions
Vonda Reeves
Renelus, Benjamin
Morehouse School of Medicine
Mastering the Medical Management of Portal Hypertension and Hepatic Encephalopathy
Benjamin Renelus
Rex, Douglas
Indiana University School of Medicine
Learning Luncheon 02: Master Class: Complex and Challenging Polyps
Douglas Rex
Quality Indicators in Colonoscopy: It's All in the Details
Douglas Rex
Rezaie, Ali
Cedars-Sinai Medical Center
Hands-on Workshop - Esophageal / Anorectal Manometry
Ali Rezaie
Hands-on Workshop - Esophageal / Anorectal Manometry
Ali Rezaie
Hands-on Workshop - Hemostasis - GI Fellows Only
Ali Rezaie
Hands-on Workshop - Hemostasis - GI Fellows Only
Ali Rezaie
Riddle, Mark
University of Nevada, Reno - School of Medicine
Enteric Infections and Foodborne Illnesses
Mark Riddle
Rinella, Mary
University of Chicago Medical Center
Emerging Medical Therapies for ALD and NAFLD
Mary Rinella
Rubin, David
University of Chicago Medicine Inflammatory Bowel Disease Center
41 - The Effect of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Results at Week 12 by Prior Inadequate Response or Intolerance to Advanced Therapy
David Rubin
Ruddy, Johannah
Rome Foundation
Neuromodulators for Functional GI Disorders – A Presentation and Panel Discussion
Johannah Ruddy
Back to Top
